Brazil Lung Cancer Therapeutics Market Report 2022 to 2030

Brazil Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Brazil Lung Cancer Therapeutics Market will reach a value of $1496 Mn from $745 Mn in 2022, growing at a CAGR of 9.1% during 2022-30. The Lung Cancer Therapeutics Market in Brazil is dominated by a few domestic pharmaceutical companies such as Eurofarma, Aché Laboratórios, and Libbs. The Lung Cancer Therapeutics Market in Brazil is segmented into different types of cancer and different therapy types. Some of the major factors affecting Brazil's lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.

ID: IN10BRPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Dr. Vishwa Modhia

Buy Now

Brazil Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Brazil Lung Cancer Therapeutics market will reach a value of $1496 Mn from $745 Mn in 2022, growing at a CAGR of 9.1% during 2022-2030.

Brazil is an upper middle-income, developing and the largest country in South America bounded by the Atlantic Ocean. Lung cancer is the second most prevalent cancer in males and the fourth most common cancer in women in Brazil, with 18,740 and 12,530 new cases anticipated for 2018. It is the main cause of cancer death in men and the second greatest cause in women. However, these figures are greatly understated due to a high rate of underdiagnosis and underreporting. Another key driving force and the necessity for lung cancer care in Brazil is the creation of appropriate disease advocacy.

Empowering advocacy groups with the assistance of long-standing organisations such as the International Association for Lung Cancer Study can foster social impulses that can persuade the government, society, and industry to take appropriate action. According to the latest WHO data published in 2020 Lung Cancers Deaths in Brazil reached 31,659 or 2.81% of total deaths. The age-adjusted Death Rate is 13.20 per 100,000 of the population ranks Brazil 87^th in the world. Brazil's government spends 10.3 % of its GDP on healthcare.

Brazil Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Between August 2015 and December 2016, 52 % of patients with lung cancer had minimally invasive anatomical lung resection, according to the Brazilian Thoracic Surgery database. Robotic-assisted thoracic surgery has recently become popular. In Brazil, the incidence of adenocarcinoma has steadily increased in comparison to that of squamous cell carcinoma; in fact, it has become the main histologic type. Furthermore, the prevalence of NSCLC has been decreasing in men while increasing in women, primarily among non-smokers. These aspects could boost Brazil's Lung Cancer Therapeutics market.

Market Restraints

Access to radiotherapy facilities is a societal issue in Brazil, with over 100,000 individuals dying each year due to a lack of proper radiation therapy. Local public health system restrictions, manifested by low per capita investments, are key impediments to the recommendation and implementation of lung cancer screening locally; additionally, practicality, cost-effectiveness, and access remain to be determined in Brazil. Brazil's healthcare system is fragmented, with both public and private providers coexisting. This might make it difficult for patients and physicians to obtain and administer lung cancer medications. High manufacturing costs limit Brazil's competitiveness (wages, energy, logistics, and loans). These factors may deter new entrants into the Brazil Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Aché Laboratórios Farmacêuticos: Aché is a Brazilian pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer.
Eurofarma Laboratórios
Cristália Produtos Químicos e Farmacêuticos
Libbs Farmacêutica

Recent Notable Updates

May 2022: Eurofarma, one of the most innovative Brazilian pharmaceutical businesses, has just announced a collaboration with Shanghai Henlius Biotech, Inc., a Chinese pharmaceutical company specialising in biologic pharmaceuticals, for the production and distribution of three biosimilars in Latin America. The firms' new licencing arrangement will allow Eurofarma to extend its line of cancer products in the countries where it operates, providing more treatment alternatives to the local market.

Healthcare Policies and Reimbursement Scenarios

Lung cancer therapeutics in Brazil are regulated and reimbursed by several bodies, including the National Health Surveillance Agency (ANVISA), the Brazilian Ministry of Health, and the Brazilian healthcare system. ANVISA oversees regulating and approving lung cancer medicines in Brazil. Through the Sistema Único de Saúde (SUS) - Unified Health System, the Brazilian healthcare system provides universal healthcare coverage to all Brazilian people. Also, certain lung cancer therapies may be offered by special programmes run by the Brazilian Ministry of Health, such as the Programa de Medicamentos de Alto Custo, which offers funds for high-cost medicines that are not normally available.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.